For instance, the duel nature of TGF-β in tumor suppressing and tumor promoting limited its role in judging the prognosis of ovarian cancer patients [8]; Matrix metalloproteinase inhibitors (MMPIs) that were designed to control ECM degradation did not improve patient survival due to lack of specificity and severe side effects [9]. This evidence concerns the gene TGFB1 and ovarian carcinoma.